Genelabs Technologies Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Redwood City CA United States (1983)
Status: Acquired by GlaxoSmithKline (2008)

Organization Overview

First Clinical Trial
1998
NCT00037128
First Marketed Drug
2001
cefaclor (ceclor)
First NDA Approval
None
Last Known Activity
2003

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

World Gen | WORLD GEN

Active Ingredients

Marketed Drugs (1)

cefaclor (ceclor) (2001)

Drugs in Phase 3 Trials (1)

prasterone (intrarosa) (3 trials)

Drugs in Phase 2 Trials (2)

trichosanthin (1 trial)

zidovudine (retrovir) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

HIV Infections (Phase 2)

Lupus Erythematosus, Systemic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3